ELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECK

Prostate-specific Antigen (psa) For Management Of Prostate Cancers

FDA Premarket Approval P000027

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the elecsys(r) free psa immunoassay for elecsys 1010 and 2010 immunoassay analyzers. The device is indicated for: the in vitro quantitative determination of free prostate-specific antigen in human serum and plasma. The elecsys free psa immunoassay is indicated for measurement of fpsa in conjunction with the elecsys total psa assay to develop a ratio (% fpsa) of fpsa to tpsa. This ratio is useful when used in conjunction with the elecsys total psa test as an aid in distinguishing prostate cancer from benign prostatic conditiond in men age 50 years or older who have a digital rectoal examination (dre) that is not suspicious for prostate cancer and an elecsys total psa value in the range 4 ng/ml to 10 ng/ml. Prostate biopsy is required for the diagnosis of prostate cancer. The electrochemiluminescene immunoassay "eclia" is intended for use on the roche elecsys 1010 and 2010 immunoassay analyzers.

DeviceELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECK
Classification NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
Generic NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
ApplicantROCHE DIAGNOSTICS CORP.
Date Received2000-07-07
Decision Date2000-12-12
Notice Date2001-01-03
PMAP000027
SupplementS
Product CodeLTJ
Docket Number00M-1683
Advisory CommitteeImmunology
Expedited ReviewNo
Combination Product No
Applicant Address ROCHE DIAGNOSTICS CORP. 9115 Hague Rd. indianapolis, IN 46250
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P000027Original Filing
S036 2021-10-18 30-day Notice
S035 2019-11-27 Normal 180 Day Track
S034 2019-01-29 Real-time Process
S033 2018-10-26 Normal 180 Day Track No User Fee
S032 2018-10-01 30-day Notice
S031 2018-04-17 Real-time Process
S030 2018-03-01 Real-time Process
S029
S028 2017-10-11 Real-time Process
S027 2017-08-28 Normal 180 Day Track
S026 2017-08-03 30-day Notice
S025 2017-05-24 30-day Notice
S024 2016-10-26 30-day Notice
S023 2016-09-07 Normal 180 Day Track No User Fee
S022 2016-02-18 30-day Notice
S021 2015-10-07 30-day Notice
S020 2014-11-25 30-day Notice
S019 2014-04-04 Real-time Process
S018 2013-04-09 Real-time Process
S017 2012-12-19 135 Review Track For 30-day Notice
S016
S015 2012-02-29 30-day Notice
S014 2012-01-31 135 Review Track For 30-day Notice
S013 2011-11-22 30-day Notice
S012 2011-08-01 Normal 180 Day Track
S011 2011-05-03 Normal 180 Day Track No User Fee
S010 2011-04-25 30-day Notice
S009 2011-04-11 135 Review Track For 30-day Notice
S008 2010-05-27 30-day Notice
S007 2008-09-02 30-day Notice
S006 2008-03-28 Normal 180 Day Track
S005 2007-07-23 Normal 180 Day Track
S004 2006-12-22 30-day Notice
S003
S002 2002-10-11 Normal 180 Day Track
S001 2001-11-07 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
04015630919338 P000027 000
04015630919321 P000027 000
04015630997053 P000027 000
04015630919338 P000027 023
04015630997053 P000027 023
04015630919321 P000027 023
04015630940011 P000027 027
07613336166673 P000027 035
07613336168134 P000027 035
07613336166628 P000027 035

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.